EUCTR2010-018738-27-DE进行中（未招募）不适用
A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients with Cystic Fibrosis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Diagnosis of CF based on the following: sweat chloride > 60 mEq/L and/or genotype with 2 identifiable mutations consistent with CF; and one or more clinical features consistent with CF.
- •2. Male and female subjects aged =18 years of age
- •3. A female subject is eligible to participate if she is of:
- •- non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea;
- •- child-bearing potential and agrees to use one of the contraception methods listed in the protocol for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until one week after the last dose.
- •4. Patients are non-smokers or former smokers by history. Former smokers will be defined as those who have not smoked for =6 months. Subjects who only use chewing tobacco products may be enrolled at the discretion of the Investigator and after consultation with the GSK medical monitor.
- •5. In the judgement of the investigator the patient is clinically stable with no change in symptoms or medication, no admissions to hospital, and no intravenous antibiotic therapy for at least 1 month prior to dosing.
- •6. Able to perform lung function tests reliably.
- •7. FEV1 >40% and <110% predicted.
- •8. Excluding periods of exacerbation, FEV1 has not decreased by >15% over the past 12 months.
- •9. Clinically colonized by a bacterial organism commonly seen in cystic fibrosis other than Burkholderia cepacia as evidenced by identification in sputum culture within the past year. To be eligible a CF patient must have colonization of at least one typical CF organism.
- •10. To be eligible, female patients must have a negative pregnancy test (urine or serum) and not be nursing at screening or prior to dosing.
- •11. Subjects must have a QTcB or QTcF < 450 msec at screening as determined by the investigators review.
- •12. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) within twice (2x) the upper limit of normal at screening and bilirubin within 1.25x ULN at screening. AST, ALT, alkaline phosphatase and bilirubin >2.0 xULN (isolated bilirubin >2.0xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- •13. Male subjects must agree to use one of the contraception methods listed in th eprotocol. This criterion must be followed from the time of the first dose of study medication until one week after the last dose.
- •14. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- •15. The subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Any clinically relevant abnormality identified on the screening medical assessment, laboratory examination, or ECG, that is not associated with cystic fibrosis.
- •Neutrophil count <1.5x109 /L
- •2. In the judgment of the PI, the patient:
- •suffers from clinically unstable pancreatic function
- •has clinically significant weight loss( =5% after a previously stable period).
- •has evidence of uncontrolled hyperglycemia or recent hypoglycemia
- •has recent change in pancreatic enzyme requirements in the past 2 months.
- •3. Recent viral infection (within 4 weeks of dosing), with or without steroid or antibiotic treatment. Presumed viral infection will be determined according to the judgment of the Investigator and no specific testing for virus will be required.
- •4. Subjects unable to produce a technically acceptable sputum sample.
- •5. Clinically significant hepatic impairment
- •Evidence of cirrhosis
- •Patients with elevated INR that is due to suspected vitamin K deficiency may be enrolled at the discretion of the Investigator and after consultation with the GSK medical monitor
- •6. Blood pressure persistently >155/95 mmHg at screening.
- •7. Positive HIV, Hepatitis B surface antigen or Hepatitis C antibody at screening.
- •8. History of regular alcohol consumption averaging >7 drinks/week for women or >14 drinks/week for men.
- •9. Urinary cotinine levels indicative of smoking.
- •10. Use of oral or parenteral corticosteroids within 4 weeks of screening.
- •11. Colonization with Burkholderia cepacia
- •12. Subjects currently being treated for mycobacterial infection
- •13. Subjects with presumed active Allergic Bronchopulmonary Aspergillosis (ABPA)
- •14. Subjects who have newly started therapy with azithromycin within the past 3 months.
- •15. In the judgment of the investigator, clinically significant hemoptysis (> 30 cc per episode) within the last 6 months
- •16. Donation of blood in excess of 500 mL within a 56-day period prior to dosing
- •17. Participation in a trial with any drug within 30 days or 5 half-lives (whichever is longer), or participation in a trial with a new chemical entity within 2 months prior to first dose of current study medication.
- •18. The subject has a positive pre-study drug/alcohol screen.
- •19. Patients may not be on an inhaled antibiotic during the study.
研究者
相似试验
已完成
不适用
A Randomized, Double Blind, Parallel Group, Placebo Controlled Outpatient Study to Examine the Safety, Tolerability and Efficacy of Single Oral Doses of Rizatriptan 10 mg and Zolmitriptan 2.5 mg for the Acute Treatment of Migraine.-G43G43PER-011-98MERCK SHARP & DOHME PERU S.R.L.,
已完成
不适用
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Post-operative Pain following Laparoscopic-assisted Gastrectomy in Early Gastric Cancer PatientsKCT0001620Vivozon60
进行中（未招募）
1 期
A study to identify whether it is safe, if it works, and how much and how often cysteamine should be given to adult patients with Cystic Fibrosis (CF) who are being treated for a worsening of CF associated lung disease.exacerbation of Cystic FibrosisMedDRA version: 19.0Level: PTClassification code 10070608Term: Infective pulmonary exacerbation of cystic fibrosisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-004986-99-ITovaBiotics, Ltd120
进行中（未招募）
1 期
A study to identify whether it is safe, if it works, and how much and how often cysteamine should be given to adult patients with Cystic Fibrosis (CF) who are being treated for a worsening of CF associated lung disease.exacerbation of Cystic FibrosisEUCTR2015-004986-99-GBovaBiotics, Ltd120
终止
不适用
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Post-operative pain following Total Hip ArthroplastyDiseases of the musculoskeletal system and connective tissueKCT0002653Vivozon20